Navigating Regulatory Pathways Across Next-Generation Treg Therapies
- Establishing a regulatory foundation: Unraveling the regulatory journey from EMA clinical success to the FDA
- Utilizing targeting and conditioning to enhance therapeutic efficacy in T1D CAR-Treg therapies
- Shaping the future of targeted Treg therapies with multi-edited allogenic CAR-Tregs across a broad range of indications